Our work therefore highlights the need to assess whether patients’ tumor cells are functionally resistant to BCL-2 inhibition with techniques such as BH3 profiling, and if that is the case, to explore switching to CD47 blockade alone rather than combining with a BCL-2 inhibitor. Here, BCL2 is linked to neoplasm.